BLOOMBERG BUSINESSWEEK: A US company will next month report the results of its study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer, also called castration-resistant prostate cancer. READ MORE>
Advertisements
Leave a Reply